LRP1 Agonism
Activation of LRP1 to Treat Chemotherapeutic Induced Peripheral Neuropathy (CIPN)
Through an exclusive global license agreement with Serpin Pharma, Dogwood Therapeutics has the rights to develop and commercialize SP16 as a treatment for cancer related pain and neuropathy.. SP16 is administered via IV formulation and has demonstrated in preclinical both anti-inflammatory (analgesic) effects, as well as the potential to repair cell tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation, and survival. Both actions have the potential to improve neuropathy associated with chemotherapy treatment.
A small, highly selective, peptide therapeutic that is 300 times more potent than its natural counterpart
By isolating the active portion of Alpha-1 Antitrypsin AAT, SP16 is a small, selective, and highly potent development candidate. When SP16 activates LRP1, it mitigates inflammation in three important ways:
1. Harmful inflammatory triggers are removed from the cell surface.
2. Key survival pathways such as ERK and AKT become activated, increasing cell resilience.
3. Pro-inflammatory pathways, including NFkB become deactivated, thereby balancing cytokine output.